Patents by Inventor Liangxing Wu

Liangxing Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20220340600
    Abstract: The present disclosure is directed to compounds of Formula (I): which modulate PD-1/PD-L1 protein/protein interaction, compositions, and methods of treating various diseases, including infectious diseases and cancer.
    Type: Application
    Filed: June 27, 2022
    Publication date: October 27, 2022
    Inventors: Jingwei Li, Liangxing Wu, Wenqing Yao
  • PYRAZOLYL BICYCLIC AMINES AS CDK2 INHIBITORS
    Publication number: 20220340579
    Abstract: The present application provides pyrazolyl bicyclic amines of Formula (I): and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: April 12, 2022
    Publication date: October 27, 2022
    Inventors: Joshua Hummel, David M. Burns, Liangxing Wu, Wenqing Yao
  • Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
    Patent number: 11472791
    Abstract: The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: October 18, 2022
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Jingwei Li, Zhenwu Li, Ding-Quan Qian, Liangxing Wu, Kaijiong Xiao, Meizhong Xu, Jeffrey C. Yang, Wenqing Yao, Fenglei Zhang, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
  • Heterocyclic compounds as immunomodulators
    Patent number: 11465981
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: October 11, 2022
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Zhiyong Yu, Fenglei Zhang, Wenqing Yao
  • IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20220315595
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
    Type: Application
    Filed: June 9, 2022
    Publication date: October 6, 2022
    Inventors: Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
  • Imidazopyridazine and imidazopyridine compounds and uses thereof
    Patent number: 11459329
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: October 4, 2022
    Assignee: Incyte Corporation
    Inventors: Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
  • Tricyclic amine compounds as CDK2 inhibitors
    Patent number: 11447494
    Abstract: The present application provides tricyclic amine compounds, which are inhibitors of cyclin-dependent kinase 2 (CDK2), of Formula (I): as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: September 20, 2022
    Assignee: Incyte Corporation
    Inventors: Qinda Ye, Ken Mukai, Liangxing Wu, Wenqing Yao
  • Tricyclic amine compounds as CDK2 inhibitors
    Patent number: 11440914
    Abstract: The present application provides tricyclic amine compounds, which are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: September 13, 2022
    Assignee: Incyte Corporation
    Inventors: Qinda Ye, Neil Lajkiewicz, Ken Mukai, Liangxing Wu, Wenqing Yao
  • SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS
    Publication number: 20220281887
    Abstract: The present application provides spirocyclic lactam compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: February 24, 2022
    Publication date: September 8, 2022
    Inventors: Stacey Shepard, Charles Cole, Nikoo Falahatpisheh, Kai Liu, Lixin Shao, Darius Vrubliauskas, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
    Patent number: 11427567
    Abstract: The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: August 30, 2022
    Assignee: Incyte Corporation
    Inventors: Qinda Ye, Jingwei Li, Ken Mukai, Brandon Smith, Liangxing Wu, Wenqing Yao, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
  • Imidazopyridazine and imidazopyridine compounds and uses thereof
    Patent number: 11427592
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: August 30, 2022
    Assignee: Incyte Corporation
    Inventors: Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
  • Heteroaryl amide compounds as sting activators
    Patent number: 11427597
    Abstract: The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: August 30, 2022
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11414433
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: August 16, 2022
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Kaijiong Xiao, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11407749
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: August 9, 2022
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Bo Shen, Jingwei Li, Zhenwu Li, Kai Liu, Fenglei Zhang, Wenqing Yao
  • Pyrido[3,2-d]pyrimidine compounds as immunomodulators
    Patent number: 11401279
    Abstract: The present disclosure is directed to compounds of Formula (I): which modulate PD-1/PD-L1 protein/protein interaction, compositions, and methods of treating various diseases, including infectious diseases and cancer.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: August 2, 2022
    Assignee: Incyte Corporation
    Inventors: Jingwei Li, Liangxing Wu, Wenqing Yao
  • Heterocyclic compounds as LSD1 inhibitors
    Patent number: 11401272
    Abstract: The present invention is directed to compounds of Formula I which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: August 2, 2022
    Assignee: Incyte Corporation
    Inventors: Chunhong He, Zhenwu Li, Liangxing Wu, Wenqing Yao, Fenglei Zhang
  • COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES
    Publication number: 20220233529
    Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor, an adenosine A2A or A2B receptor inhibitor, and a PD-1/PD-L1 inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 and/or PD-1/PD-L1 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies, PD-1/PD-L1 inhibitors, and A2A/A2B inhibitors are also disclosed.
    Type: Application
    Filed: December 29, 2021
    Publication date: July 28, 2022
    Inventors: Hui Wang, Juan Carlos Almagro, Rebecca A. Buonpane, Peter Niels Carlsen, Taisheng Huang, Yong Li, Horacio G. Nastri, Chao Qi, Shaun M. Stewart, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Jing Zhou, Wenyu Zhu
  • Substituted spiro[cyclopropane-1,5?-pyrrolo[2,3-d]pyrimidin]-6?(7?h)-ones as CDK2 inhibitors
    Patent number: 11384083
    Abstract: The present application provides pyrrolo[2,3-d]pyrimidinone inhibitors of cyclin-dependent kinase 2 (CDK2) of Formula (I): as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: July 12, 2022
    Assignee: Incyte Corporation
    Inventors: Alexander Sokolsky, Sarah Winterton, Liangxing Wu, Wenqing Yao
  • DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS
    Publication number: 20220213108
    Abstract: The present application provides deazaguaine compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: December 20, 2021
    Publication date: July 7, 2022
    Inventors: Andrew W. Buesking, Onur Atasoylu, Cheng-Tsung Lai, Padmaja Polam, Liangxing Wu, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20220213090
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 24, 2021
    Publication date: July 7, 2022
    Inventors: Liangxing Wu, Neil Lajkiewicz, Chunhong He, Kaijiong Xiao, Wenyu Zhu, Zhenwu Li, Song Mei, Chao Qi, Leah C. Konkol, Wenqing Yao